Ftse Mib
34.160,97
1,25%
DAX
19.984,32
0,74%
S&P 500
5.970,84
-1,11%
NASDAQ
19.722,03
-1,49%
Bitcoin
94.862,80
-0,29%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Evaxion Biotech AS (EVAX) Evaxion Biotech AS (EVAX) Notizie

EVAX

Evaxion Biotech AS (EVAX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EVAX
DataOraFonteTitoloSimboloCompagnia
26/12/202422:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
17/12/202423:09Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:EVAXEvaxion Biotech AS
17/12/202414:00GlobeNewswire Inc.Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equityNASDAQ:EVAXEvaxion Biotech AS
12/12/202414:00GlobeNewswire Inc.Evaxion establishes new AI-derived precision cancer vaccine conceptNASDAQ:EVAXEvaxion Biotech AS
09/12/202414:00GlobeNewswire Inc.Evaxion announces 2025 milestones reflecting continued strong strategy executionNASDAQ:EVAXEvaxion Biotech AS
02/12/202414:00GlobeNewswire Inc.Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology CongressNASDAQ:EVAXEvaxion Biotech AS
18/11/202422:30Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:EVAXEvaxion Biotech AS
13/11/202414:00GlobeNewswire Inc.Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listingNASDAQ:EVAXEvaxion Biotech AS
12/11/202414:00GlobeNewswire Inc.Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1NASDAQ:EVAXEvaxion Biotech AS
31/10/202413:00GlobeNewswire Inc.Evaxion announces business update and third quarter 2024 financial resultsNASDAQ:EVAXEvaxion Biotech AS
28/10/202413:00GlobeNewswire Inc.Evaxion to announce business update and third quarter 2024 financial results on October 31NASDAQ:EVAXEvaxion Biotech AS
09/10/202414:00GlobeNewswire Inc.Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trialsNASDAQ:EVAXEvaxion Biotech AS
03/10/202414:00GlobeNewswire Inc.Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platformNASDAQ:EVAXEvaxion Biotech AS
26/09/202413:30GlobeNewswire Inc.Evaxion significantly expands vaccine development collaboration with MSDNASDAQ:EVAXEvaxion Biotech AS
19/09/202414:00GlobeNewswire Inc.Evaxion launches improved AI-Immunology™ platform for vaccine antigen predictionNASDAQ:EVAXEvaxion Biotech AS
16/09/202413:00GlobeNewswire Inc.Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01NASDAQ:EVAXEvaxion Biotech AS
09/09/202414:00GlobeNewswire Inc.Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01NASDAQ:EVAXEvaxion Biotech AS
09/09/202413:00GlobeNewswire Inc.Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2NASDAQ:EVAXEvaxion Biotech AS
23/08/202414:30Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:EVAXEvaxion Biotech AS
23/08/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:EVAXEvaxion Biotech AS
14/08/202413:00GlobeNewswire Inc.Evaxion Announces Business Update and Second Quarter 2024 Financial ResultsNASDAQ:EVAXEvaxion Biotech AS
12/08/202413:27GlobeNewswire Inc.Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14NASDAQ:EVAXEvaxion Biotech AS
08/08/202414:00GlobeNewswire Inc.Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in SeptemberNASDAQ:EVAXEvaxion Biotech AS
16/07/202413:30GlobeNewswire Inc.Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology ConferenceNASDAQ:EVAXEvaxion Biotech AS
03/07/202414:05GlobeNewswire Inc.Evaxion Reinforces Milestone Timeline and Provides Shareholder UpdateNASDAQ:EVAXEvaxion Biotech AS
26/06/202413:30GlobeNewswire Inc.Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification MethodNASDAQ:EVAXEvaxion Biotech AS
17/06/202414:44GlobeNewswire Inc.Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical JournalNASDAQ:EVAXEvaxion Biotech AS
03/06/202414:00GlobeNewswire Inc.Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024NASDAQ:EVAXEvaxion Biotech AS
28/05/202414:21GlobeNewswire Inc.Evaxion Announces Business Update and First Quarter 2024 Financial ResultsNASDAQ:EVAXEvaxion Biotech AS
23/05/202423:00GlobeNewswire Inc.Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024NASDAQ:EVAXEvaxion Biotech AS
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:EVAX

La tua Cronologia

BIT
P166S6
BNP Paribas Issuance
BIT
UC1TAJ
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network